Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved64Cu PET

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1139-1146

  Li, Lin ^a   Turatti, Fabio ^b   Crow, Desiree ^a   Bading, James R ^a   Anderson, Anne Line ^a   Poku, Erasmus ^a   Yazaki, Paul J ^a   Williams, Lawrence E ^c   Tamvakis, Debra ^b   Sanders, Paul ^b   Leong, David ^b   Raubitschek, Andrew ^a   Hudson, Peter J ^b   Colcher, David ^a   Shively, John E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SolveIT Software Pty Ltd   (Australia)

^c City of Hope ^*  (United States)

Author keywords

64Cu, polyethylene glycol; CC49; Diabody; DOTA; PET; TAG 72

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY; ANTIBODY CONJUGATE; COPPER 64; INDIUM 111; IODINE 125; MACROGOL; TAG 72 DIABODY; UNCLASSIFIED DRUG; COPPER; DIAGNOSTIC AGENT; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SYNTHESIS; DRUG TUMOR LEVEL; DRUG UPTAKE; ESCHERICHIA COLI; HALF LIFE TIME; KIDNEY METABOLISM; KIDNEY TUBULE ABSORPTION; MOLECULAR SIZE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; GEL CHROMATOGRAPHY; IMMUNOCHEMISTRY; ISOELECTRIC FOCUSING; KIDNEY; MASS SPECTROMETRY; METABOLISM; MOLECULAR CLONING; NEOPLASM; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; ULTRACENTRIFUGATION;

ANIMALS; CHROMATOGRAPHY, GEL; CLONING, MOLECULAR; COPPER RADIOISOTOPES; IMMUNOCHEMISTRY; IMMUNOGLOBULIN G; ISOELECTRIC FOCUSING; KIDNEY; MASS SPECTROMETRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; ULTRACENTRIFUGATION;

EID: 77954981358     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.074153     Document Type: Article

References (37)

1. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191-197.
2. Williams LE, Wu AM, Yazaki PJ, et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radiopharm. 2001;16:25-35.
3. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126-1136.
4. Williams LE, Lopatin G, Kaplan DD, Liu A, Wong JY. Update on selection of optimal radiopharmaceuticals for clinical trials. Cancer Biother Radiopharm. December 27, 2008 [Epub ahead of print].
5. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44:1962-1969.
6. 111In-labeled DOTA conjugated antibody fragments. Bioconjug Chem. 2001;12:264-270.
7. Olafsen T, Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005;65:5907-5916.
8. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
9. Li L, Olafsen T, Anderson AL, Wu A, Raubitschek AA, Shively JE. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments: site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem. 2002;13:985-995.
10. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 2003;16:761-770.
11. Delgado C, Pedley RB, Herraez A, et al. Enhanced tumour specificity of an anticarcinoembrionic antigen Fab' fragment by poly (ethylene glycol) (PEG) modification. Br J Cancer. 1996;73:175-182.
12. Lee LS, Conover C, Shi C, Whitlow M, Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem. 1999;10:973-981.
13. Albrecht H, Denardo GL, Denardo SJ. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging. 2007;51:304-313.
14. Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009;284:25612-25619.
15. Leong SR, DeForge L, Presta L, et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using sitespecific pegylation. Cytokine. 2001;16:106-119.
16. Li L, Yazaki PJ, Anderson AL, et al. Improved biodistribution and radioimmunoimaging with poly (ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem. 2006;17:68-76.
17. Kobayashi H, Le N, Kim IS, et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999;59:422-430.
18. 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents. Nucl Med Biol. 2002;29:795-801.
19. Li L, Bading J, Yazaki PJ, et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem. 2008;19:89-96.
20. Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem. 1998;9:72-86.
21. Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem. 2001;12:220-228.
22. Li L, Tsai SW, Anderson AL, Keire DA, Raubitschek AA, Shively JE. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies: conjugates retain immunoreactivity and have similar biodistributions. Bioconjug Chem. 2002;13:110-115.
23. Williams LE, Liu A, Wu AM, et al. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med Phys. 1995;22:2025-2027.
24. Yazaki PJ, Shively L, Clark C, et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J Immunol Methods. 2001;253:195-208.
25. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806-2811.
26. Santos AD, Kashmiri SV, Hand PH, Schlom J, Padlan EA. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Cancer Res. 1999; 5 (10, suppl) 3118s-3123s.
27. Chauhan SC, Jain M, Moore ED, et al. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging. 2005;32:264-273.
28. Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol. 2005;32:157-164.
29. 99mTc- labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med. 2001;42:1519-1527.
30. Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6:3095-3102.
31. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35:1017-1022.
32. Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 singlechain antibody. Int J Cancer. 1999;81:911-917.
33. Gangopadhyay A, Bajenova O, Kelly TM, Thomas P. Carcinoembryonic antigen induces cytokine expression in Kupffer cells: implications for hepatic metastasis from colorectal cancer. Cancer Res. 1996;56:4805-4810.
34. Gangopadhyay A, Thomas P. Processing of carcinoembryonic antigen by Kupffer cells: recognition of a penta-peptide sequence. Arch Biochem Biophys. 1996;334:151-157.
35. Jessup JM, Petrick AT, Toth CA, et al. Carcinoembryonic antigen: enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer. 1993;67:464-470.
36. Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem. 2005;16:113-121.
37. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304-310.